ArticleBMC cancer2026
NAT10 promotes the glycolysis of retinoblastoma through ac4C modification of PFKFB3 mRNA.
Article in BMC cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- NAT10 as a central node in cancer biology: integrating epitranscriptomic regulation, metabolic reprogramming, and immune modulation.Frontiers in immunology · 2026Review
- Post-translational modifications in retinoblastoma: mechanisms, immune regulation, and therapeutic opportunities.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Retinoblastoma (RB) is the most prevalent primary intraocular malignancy in children. N-acetyltransferase-like protein 10 (NAT10)-mediated N4-acetylcytidine (ac4C) modification is involved in regulating cancer progression. This study aimed to elucidate the role and underlying mechanisms of NAT10 in RB progression. The cell viability was detected by CCK-8 assay. The cell glycolysis was evaluated by glucose uptake, lactate production, extracellular acidification rate (ECAR), and oxygen consumption rate (OCR) assays. The underlying molecular mechanism was investigated by dot blot, western blot, quantitative real-time PCR, RNA immunoprecipitation (RIP), ac4C RIP, and dual-luciferase reporter assay. Results showed elevated NAT10 and ac4C levels in RB cells. Genetic modulation of NAT10 bidirectionally regulated glycolysis, with 2‑deoxy‑D‑glucose (2‑DG) attenuating NAT10-induced glycolytic activation. Mechanistically, NAT10 bound PFKFB3 and stabilized its mRNA via ac4C modification. PFKFB3 overexpression rescued glycolytic suppression caused by NAT10 knockdown. In vivo, NAT10 promoted tumor growth. Collectively, NAT10 contributes to RB progression by enhancing glycolysis through ac4C-mediated PFKFB3 mRNA stabilization, identifying the NAT10-ac4C-PFKFB3 axis as a potential therapeutic target.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.